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ABSTRACT
Podoplanin (PDPN), an O-glycosylated, transmembrane, mucin-type glycoprotein, 
is expressed by cancer associated fibroblasts (CAFs). In malignant transformation, 
PDPN is subjected to changes and its role is yet to be established. Here we show that 
it is involved in modulating the activity of the CCL21/CCR7 chemokine/receptor axis 
in a hypoxia-dependent manner. In the present model, breast cancer MDA-MB-231 
cells and NKL3 cells express the surface CCR7 receptor for CCL21 chemokine which is 
a potent chemoattractant able to bind to PDPN. The impact of the CCL21/CCR7 axis 
in the molecular mechanism of the adhesion of NKL3 cells and of MDA-MB-231 breast 
cancer cells was reduced in a hypoxic tumor environment. In addition to its known 
effect on migration, CCL21/CCR7 interaction was shown to allow NK cell adhesion 
to endothelial cells (ECs) and its reduction by hypoxia. A PDPN expressing model of 
CAFs made it possible to demonstrate the same CCL21/CCR7 axis involvement in the 
tumor cells to CAFs recognition mechanism through PDPN binding of CCL21. PDPN was 
induced by hypoxia and its overexpression undergoes a reduction of adhesion, making 
it an anti-adhesion molecule in the absence of CCL21, in the tumor. CCL21/CCR7 
modulated NK cells/ECs and MDA-MB-231 cells/CAF PDPN-dependent interactions 
were further shown to be linked to hypoxia-dependent microRNAs as miRs: miR-210 
and specifically miR-21, miR-29b which influence PDPN expression.
INTRODUCTION
In the tumor microenvironment and in the secondary 
lymphoid organs, CCL21 chemokine is a potent and 
specific chemoattractant upon presentation on the surface 
of endothelial cells via glycosaminoglycans (GAGs) [1]. 
In non-transformed cells, it is constitutively expressed 
by high endothelial cells in lymph nodes and Peyer’s 
patches, lymphatic ECs as well as stromal cells in the 
spleen and appendix [2]. Its receptor, CCR7, is present 
on subpopulations of T cells [3], semi-mature and mature 
dendritic cells (DCs) [4], natural killer (NK) and natural 
killer T (NKT) [5, 3] cells. CCL21 interaction with its 
transmembrane receptor activates integrins which mediate 
the firm adhesion of leukocytes to endothelium [6]. CCL21, 
together with CCL19 and the highly O-glycosylated, mucin-
type glycoprotein called podoplanin (PDPN) are required for 
normal lymphoid tissue organization. This is essential for 
effective T cell-DC interactions [7, 8, 9]. Lymphatic ECs 
secrete CCL21 in a complex, together with PDPN which 
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was shown to attract CCR7+ cells [10]. Tumor growth 
inhibition was evidenced upon CCL21 expression in colon 
carcinoma and murine models of melanoma as well as 
mammary carcinoma [12, 15, 16]. CCL21-mediated help of 
tumor regression was shown to depend on host T and NK 
cell activity [11].
CCR7 is also expressed by non-immune cells, most 
notably in malignancies [12]. In many tumor types, including 
MDA-MB-231 breast cancer cells, expression of CCR7 
drives metastases into lymph nodes [13]. This also occurs in 
melanoma [14, 15], colorectal cancer [16, 17], non-small cell 
lung cancer [18], and chronic lymphocytic leukemia [19].
In these malignancies, interaction of CCR7 with 
CCL21 drives migration and invasion of CCR7+ cancer 
cells into lymph nodes similarly to normal homing [18, 
20]. Furthermore the effect of CCR7 on tumor progression 
in primary mouse and human breast tumors is mediated 
through stem-like cells by decreasing their ability to self-
renew and triggering neoplasia [21].
Podoplanin expression has been studied in a variety 
of cancer cells in relation to lymphatic vasculature [22]. 
In vivo, its overexpression in MCF-7 breast cancer cells 
promotes metastasis into lymph nodes [23]. It induces 
platelet aggregation with circulating tumor cells, which 
helps metastasis [24, 25]. In mammary tumors, cancer 
associated fibroblasts (CAFs) which constitute a major 
cell component of the stroma, express PDPN but little is 
known about its mechanism of expression [26, 27] and 
modulation. This may be crucial for the movement of 
cancer cells, more specifically cancer stem cells which 
differently express cell adhesion molecules [28], for their 
ability to escape the tumor site. According to this theory 
a key role in the control of tumor microenvironment 
is played by microRNAs (miRs) on gene expression 
occurring post-transcriptionally [29]. Among others, miR-
21 is a regulator of the oncogenic process since it regulates 
cell proliferation, survival and migration of most cancer 
cells through its target proteins [30], mainly the tumor 
suppressor PTEN (phosphatase and tensin homologue 
deleted on chromosome ten) the activity of which 
correlates with miR-301 [31]. Since PTEN controls tumor 
growth and metastasis by regulating tumor angiogenesis 
[32] it controls the hypoxic status inside the tumor, thereby 
possibly alleviating hypoxia in tumors.
Therefore, the aim of the present study was to 
analyze the molecular mechanisms of the recognition 
of CCR7+NK cells and microvascular ECs in order to 
decipher their role in the NK cells recruitment into tumors. 
Moreover, the effect of CCL21 availability to breast cancer 
cells, through PDPN expression by CAFs, was addressed. 
PDPN is shown to be modulated by hypoxia and related 
to miR-21, miR-210 and miR-29b expression in CAF-like 
fibroblasts. This work demonstrates that tumor hypoxia, 
by modulating the expression of molecules such as PDPN, 
leads to easier liberation of tumor cells and, lowering the 
NK cells recruitment upon CCL21 presentation, it impairs 
the anti-tumor immune defence. These studies, conducted 
under conditions mimicking the tumor microenvironment 
show the fundamental influence of hypoxia on PDPN 
expression by fibroblasts and its presentation of CCL21 to 
CCR7+ tumor cells and CCR7+ NK cells.
RESULTS
CCR7 expression and cell adhesion properties 
of NK cells to endothelial cells from peripheral 
lymph nodes
Three different NK cell lines [33, 34] were 
characterized for CCR7 expression on their surface 
(Figure 1). NKL1 cells did not express CCR7. In contrast, 
NKL2 and NKL3 cells expressed the receptor; NKL3 
displayed a higher level of expression than NKL2 cells 
(Figure 1A). Figure 1B provides the quantification of the 
adhesion of the NK cell lines, tested on human peripheral 
lymph node endothelial HPLNEC.B3 cells [35] under flow 
conditions, which correlates with CCR7 expression on the 
NK lines (Figure 1A, 1B). Figure 1C shows that NKL3 
adhered more efficiently to HPLNEC.B3 cells under flow 
(Figure 1C e, f) when compared to NKL1 (Figure 1C a, b) 
and NKL2 (Figure 1C c, d). However, the latter cell line 
adheres more efficiently than NKL1 cells.
The influence of CCL21 activity and hypoxia on 
adhesion properties of NKL3
CCL21 is known as a chemoattractant for many 
immune cells, in particular NK cells. The mechanism 
of attraction is potentially endothelial cell-mediated. To 
assess the possible changes in chemokine production by 
endothelial cells under hypoxia, CCL21 was quantified by 
ELISA in the cell lysates of HPLNEC.B3 cells cultured 
under normoxia or hypoxia (Figure 2A). It appeared that 
significantly less CCL21 was produced under hypoxia 
than normoxia although its mRNA expression was highly 
increased under hypoxic conditions (Supplementary 
Figure 1). This may possibly influence the recruitment and 
adhesion level of NK cells on hypoxic endothelial cells.
The role of ECs CCL21 was assessed by pre-
incubation of HPLNEC.B3 cells in the presence of 
exogenous CCL21 prior to the measurement of NKL3 
cell adhesion. Under normoxic control conditions, the 
adhesion level of NKL3 cells to endothelial cells when 
pre-stimulated by CCL21 was 6.5 times higher than 
towards non stimulated cells (Figure 2B). Hypoxia is one 
of the main characteristics of tumor microenvironments. 
Its influence on NK cell adhesion properties was 
investigated. Hypoxia is known to regulate some adhesion 
molecule expression, and this can especially be observed 
on HPLNEC.B3 cells. This could explain the observed 
adhesion decrease [34, 36]. But, another hypothesis could 
be put forward based on the expression and activity of 
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CCL21 which is the main chemokine involved in cell 
recruitment into lymphoid organs.
To mimic intra tumor conditions HPLNEC.B3 cells 
were submitted to hypoxia (1%) for 24 hours prior to the 
adhesion assay testing for the involvement of CCL21. 
Figure 2B shows that NKL3 cells had 70% less adhesion 
to hypoxia-treated HPLNEC.B3 than in normoxia. Upon 
treatment by CCL21 the adhesion level was increased 
6 fold although it remained 4.5 times lower than with 
CCL21 treatment in normoxia. This shows the effect of 
tumor microenvironment conditions on the efficacy of the 
antitumor immune cells.
Capping of CCR7 receptor induces an increase 
of NKL3 cell adhesion
The adhesion process is highly dependent on cell 
energy and metabolism. To distinguish the pathways by 
Figure 1: Adhesion of NK cell lines on endothelial cells from peripheral lymph nodes (HPLNEC.B3 cells). A. Expression 
of the CCL21 receptor (CCR7) on NKL1, NKL2 and NKL3 cells surface. Results represent Δ MFI (mean fluorescence intensity) from flow 
cytometry analysis. Values marked with a star vary significantly (p<0.05, N=5) from the NKL1 level of expression. B. Quantification of 
adhered NK cells counted from ten representative fields. Values marked with a star vary significantly (p<0.05, N=3) from NKL1 and NKL2 
adhesion levels. C. Flow adhesion data of NKL cell lines on HPLNEC.B3 cells NKL1 (a, b); NKL2 (c, d) ; (e, f).
Figure 2: Influence of CCL21 presentation by peripheral lymph node endothelial cells and hypoxia on NK cells 
recognition and adhesion. A. Hypoxia vs normoxia CCL21 production by HPLNEC.B3 cells measured by ELISA in cell lysates. 
Concentration of CCL21 protein produced under normoxia was set as 100%. Values marked with a star vary significantly (p<0.05, N=3). 
B. Quantification of the NKL3 adhesion to HPLNEC.B3 as number of NKL3 cells counted on the surface of HPLNEC.B3 cells (ten 
representative fields were counted) in normoxia and in hypoxia showing a reduction before as well as after treatment with CCL21. NK cells 
were labelled by the PKH26 red fluorescent cell linker kit. NK cells were injected on the HPLNEC.B3 cells monolayer (1.106 NK cells/
ml) at a fixed flow rate of 0, 2 dyn/cm2 for 5 minutes and washing by OptiMEM at 0, 6 dyn/cm2 for 10 min. Adhered NK cells amount was 
quantified. *** p<0.001, N=3, ### p<0.001, N=3.
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which CCR7 might be involved in adhesion/recognition, 
its dynamic status was checked on NKL3 cell membranes. 
When cells were exposed to mouse anti-CCR7 FITC 
coupled antibodies at 4°C and then fixed with PFA, the 
receptor was found dispersed on the plasma membrane 
(Figure 3A). However, when cells were similarly labelled 
at 4°C and then at room temperature, i.e. 25°C, for 5 
minutes, CCR7 concentrated into patches (Figure 3B). 
After 15 min. incubation at 25°C, receptors clustered into 
polar caps (Figure 3C, arrows).
The dynamic redistribution of CCR7 on the cell 
surface greatly influenced the adhesion properties of NKL3 
cells. When NKL3 cells were first treated by CCL21 a 
considerable effect on the adhesion efficacy was observed 
(Figure 3D) and when CCL21 receptor-CCR7 capping 
induction was permitted by a temperature jump from 4°C 
to 25°C (15 min.), NKL3 cells adhered more efficiently 
on HPLNEC.B3 cells (Figure 3D). This indicates the role 
of CCL21 and the dynamics of its receptor in the adhesion 
process of NK cells to endothelial cells.
CCR7-CCL21 axis role in the recognition 
mechanism of NKL cells to HPLNEC.B3 cells
As described above, when HPLNEC.B3 cells were 
pre-incubated with exogenous CCL21, the adhesion level 
of NK cells was strongly increased confirming previous 
studies [34, 6]. To decipher the molecular mechanism of 
the interaction, HPLNEC.B3 cells were pre-incubated with 
exogenous CCL21 showing a 30% increase of the NKL3 
numbers of adhered cells (Figure 4A) in normoxia. This 
adhesion increase by CCL21 was prevented when NKL3 
cells were pre-incubated with anti-CCR7 neutralizing 
antibodies. Then the adhesion of NKL3 cells remained 
at the basal control level (obtained when NKL3 were 
incubated with anti-CCR7 antibodies). This confirmed 
the CCR7/CCL21 implication in the increase of NK cell 
adhesion to endothelial cells. Moreover, if HPLNEC.
B3 pre-incubation with CCL21 was performed in the 
presence of chondroïtin sulfate E, the adhesion increase 
was abrogated while incubation of HPLNEC.B3 cells 
with only chondroitin sulfate E did not affect adhesion 
compared to control.
These experiments were performed under hypoxic 
conditions so the endothelial cells could mimic the tumor 
microenvironment (Figure 4B). It was confirmed that 
NKL3 basic adhesion was reduced when compared to 
normoxia. CCL21 treatment of HPLNEC.B3 induced a 
high increase of the adhesion (2.5 fold). Similar to data 
obtained under normoxic conditions, CCR7 involvement 
in NKL3 cells was shown by the total inhibition obtained 
upon blocking the receptor with anti CCR7 neutralizing 
antibodies. Moreover chondroitin sulfate E-mediated 
inhibition of increase of adhesion due to CCL21, was 
Figure 3: CCR7 detection, dynamics and activity on NKL3 cells. A. NK cells labelled with FTC-anti-CCR7 antibodies, at 4°C 
and fixed with 4% PFA, capping does not occur. B. Patching upon warming the cells from 4°C to 25°C for 5 min. at 25°C. C. Warming for 
15 mins, capping occurs. D. Quantification of the NKL3 cells adhesion to HPLNEC.B3 as number of NKL3 cells counted on the surface of 
HPLNEC.B3 cells monolayer (ten representative fields were counted), NKL3 were either maintained at room temperature or capping was 
induced (4-25°C) before and after preincubation with CCL21 *p<0.05, **p<0,01, N=3, # p<0.05, ## p<0,01 N=3.
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total, indicating chemokine presentation by endothelial 
glycosaminoglycan. In hypoxia, this is accompanied 
by an increase of the chondroitin sulfate expression by 
HPLNEC.B3 cells (up to 71% by 48 H) as shown by A. 
Selo (doctoral thesis).
To characterize the chemokine CCL21 interaction 
with glycosaminoglycans of the chondroitin sulfate family, 
a direct binding assay was performed by surface plasmon 
resonance. The CCL21 binding to fixed chondroitin and 
concentration dependency is shown in Figure 4C, while 
the specificity for the E form of chondroitin sulfate is 
demonstrated in Figure 4D. This shows a competitive 
inhibition of the binding of CCL21 to chondroitin sulfate 
B (high molecular weight) by synthetic tetrasaccharides of 
the ChE type compared to tetrasaccharides of the D, B and 
C forms of chondroitin sulfate.
CCL21/CCR7 implication in tumor cell adhesion 
to fibroblasts expressing podoplanin
The role of the CCL21/CCR7 axis in the breast 
tumor microenvironment was further analysed for the 
tumor cell interaction with stromal cells, namely the 
cancer associated fibroblasts. For this purpose the human 
breast cancer model MDA-MB-231 was chosen for its 
aggressive properties and expression of CCR7 as shown 
in Supplementary Figure 2 as compared to the non-
aggressive MCF-7 breast cancer cell line. To represent a 
CAF cell model, MSU1.1 human fibroblastic cells were 
transduced to express podoplanin (MSU1.1 PDPN) as 
described in Materials and Methods. As shown in Figure 5, 
PDPN was found to be expressed both at the mRNA level 
(Figure 5A) and the protein level (Figure 5B) and in cells, 
by immunochemistry (Figure 5C). Podoplanin expression 
is modulated by hypoxia as shown in (Figure 5D, 5E). The 
mRNA level of PDPN was higher (1.8 fold) upon hypoxia 
treatment (Figure 5D), and confirmed at the protein level 
by immunoblotting (Figure 5E). The role of PDPN in the 
adhesion process of MDA-MB-231 cells to CAFs was 
studied. Adhesion was reduced by 50%, when MSU1.1 
cells expressed PDPN as compared to the control cells 
transduced by the empty vector, as shown in Figure 5F, 
when experiments were conducted under flow conditions. 
Similar to NKL3 cell adhesion processes, MDA-MB-231 
adhered more efficiently in normoxia (Figure 5G) than in 
hypoxia (Figure 5H) on MSU1.1 PDPN.
Figure 4: A. Impact of CCL21 presentation by GAGs on CCR7+ NK cells adhesion to endothelial cells. Quantification of the NKL3 
adhesion to HPLNEC.B3 as number of NKL3 cells counted on the surface of HPLNEC.B3 cells (ten representative fields were counted) in 
normoxia (A) and in hypoxia B. showing an increase in adhered NKL3 after treatment with CCL21 and decrease after treatment with CCR7 
neutralizing antibody and chondroitin sulfate in both conditions. NK cells were labelled by PKH26 red fluorescent cell linker kit then, 
treated or not with CCR7 neutralizing antibodies (10 μg/ml), or ChSE (0,6 μg/ml) for 1 hour at 4°C. Then, NK cells were injected on the 
HPLNEC.B3 cells monolayer (1.106 NK cells/ml in OptiMEM) at a fixed flow rate of 0, 2 dyn/cm2 for 5 minutes and washing by OptiMEM 
at 0, 6 dyn/cm2 for 10 min. Adhered NK cells amount was quantified. * p<0.05, N=3, # p<0.05, N=3; ** p<0.005, N=3, ## p<0.005, N=3. 
C. Plasmon resonance assessment of the affinity of CCL21 chemokine for various glycosaminoglycans. CCL21 was injected over the GAG 
surface in a range of concentrations (from 0 to 300 nM) to produce sensorgrams for association and dissociation phases analysis. Binding 
kinetics were evaluated with a 1:1 Langmuir model using the BiaEvaluation software (Biacore). D. Inhibition experiments by co-injection 
of CCL21 chemokine with various concentrations of GAGs on the immobilized ChSD surface. Relative inhibition was preferential for 
chondroitin sulphate E compared to ChS B, D and C.
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Upon pre-incubation of the MSU1.1 PDPN in the 
presence of CCL21 no significant change was observed 
in the adhesion when performed in normoxia (Figure 
5G) while it significantly increased the adhesion of 
MDA-MB-231 cells in hypoxia (Figure 5H). Under both 
oxygen tension conditions, adhesion was inhibited by 
pre-incubation of the cancer cells MDA-MB-231 in the 
presence of neutralizing anti-CCR7 antibodies (Figure 
5G, 5H) which bound efficiently to MDA-MB-231 
(Supplementary Figure 2).
This effect is obtained under hypoxic conditions 
(Figure 5H). Indeed, when MSU1.1 PDPN cells were 
pre-incubated with exogenous CCL21, the adhesion level 
of MDA-MB-231 cells was clearly (2 fold) increased 
(Figure 5H). This increased adhesion effect which was 
displayed after CCL21 treatment only in hypoxia, was 
totally inhibited upon blocking the CCR7 receptors on 
the MDA-MB-231 cancer cells (Supplementary Figure 2) 
by pre-incubation with anti-CCR7 neutralizing antibodies 
(Figure 5H). This shows the involvement of the same 
CCL21/CCR7 axis in the tumor cell to cancer associated 
fibroblast recognition.
Figure 5I displays the same type of experiment on 
non PDPN expressing MSU1.1 fibroblasts, in normoxia, 
pointing to the higher adhesion activity of MDA-MB-231 
cells. In normoxia, the CCR7 inhibition effect indicates 
that the CCR7/CCL21 axis is involved in the recognition 
similar to PDPN expressing fibroblasts in normoxia 
(Figure 5G). Indeed, CCL21 has no effect on MSU1.1 
adhering capacity, thus pointing to a PDPN/CCL21 
interaction, as evidenced in hypoxia, on CAFs. The data 
obtained upon adhesion of MDA-MB-231 on MSU1.1 non 
expressing PDPN in hypoxia (Supplementary Figure 3) 
were similar to normoxia, confirming that in CAFs, PDPN 
Figure 5: Impact of podoplanin/CCL21 interaction on MDA-MB-231 cells adhesion to MSU1.1 and MSU1.1 PDPN 
cells surface in normoxia and hypoxia. A. Quantification of podoplanin expression at mRNA level in hypoxia vs normoxia. B. PDPN 
protein detection by immunoblotting. C. PDPN protein detection (b) in cells by immunocytochemistry with AlexaFuor-murine IgG anti 
human PDPN (green), nuclei are labelled with DRAG-5 (red). Control (a) is MSU1.1 NC cells (transduced with empty vector). D. PDPN 
mRNA expression level in hypoxia vs normoxia in MSU1.1 PDPN. E. PDPN protein expression level in hypoxia vs normoxia in MSU1.1 
PDPN. F. Quantification of the MDA-MB-231 cells adhesion to MSU1.1 and MSU1.1 PDPN cells surface. MDA-MB-231 cells were 
counted on the surface of MSU1.1 NC or MSU1.1 PDPN cells (ten representative fields were counted) after flow adhesion in normoxia. * 
p<0.05, N=3 (mean from ten representative fields). G. Effect of CCL21/CCR7 interaction on MDA-MB-231 cell adhesion onto MSU 1.1 
PDPN cells in normoxia. H. Effect of CCL21/CCR7 interaction on MDA-MB-231 cell adhesion on MSU1.1 PDPN cells in hypoxia. I. 
Effect of CCL21/CCR7 interaction on MDA-MB-231 cell adhesion on MSU1.1 NC cells in normoxia. J. Reduction of adhesion of NKL3 
cells to MSU1.1 PDPN vs MSU1.1 NC and MSU 1.1.
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can interact with CCL21 to bind CCR7+ cells. It must be 
pointed out that NKL3 cells, similar to MDA-MB-231 
cancer cells, adhere less to PDPN expressing fibroblasts. 
This confirms an antiadhesive effect of PDPN in the tumor 
stroma (Figure 5J). While this effect is compensated for 
by the addition of CCL21 in vitro, no increase of the 
CCL21 level was observed with hypoxia in fibroblasts 
(Supplementary Figure 4).
miRNAs expression in normoxia and hypoxia in 
MSU1.1 and MSU1.1 PDPN
MSU1.1 and MSU1.1 PDPN cells were incubated 
in hypoxia and normoxia for 24 h and miR-210, miR-21 
and miR-29b expression levels were evaluated using real-
time qPCR. In MSU1.1 cells, the level of miR-210 was 
8.19 fold higher in hypoxia than in normoxia. In MSU1.1 
PDPN cells the level of miR-210 was 7.73 fold higher in 
hypoxia than in normoxia (Figure 6A). The expression 
level of miR-21 in MSU1.1 cells was increased 1.66 fold 
with hypoxia treatment when compared to normoxia. In 
MSU1.1 PDPN cells this increase was 4.7 fold (Figure 
6B). The expression of MiR-29b, a known regulator of 
PDPN expression, increased 3.06 fold only in MSU1.1 
PDPN expressing cells. In MSU1.1 cells, no difference 
was observed for miR-29b expression in hypoxia vs 
normoxia.
DISCUSSION
One of the main pitfalls of anticancer 
immunotherapeutic strategies is the lack of accessibility 
of tumor cells to drugs and the hypoxic conditions of 
the tumor microenvironment which favor cancer stem-
like cell selection and immunosuppression [32, 37, 28]. 
Thus the factors that determine NK cells migration into 
the tumor microenvironment must be known in order to 
better understand the mechanism of NK cells infiltration 
and improve their efficacy in anti-tumor therapies. One 
approach is to modify the tumor microenvironment in 
order to allow an efficient NK cell attraction and prevent 
their inactivation within the tumor by the action of 
immune checkpoint molecules [38].
In this work two important factors associated with 
tumor microenvironment were considered since they 
affect NK cell recruitment, recognition and activity. 
These factors are hypoxia, which accompanies and 
helps immunosuppression in solid tumors [32, 39], and 
chemokines which stimulate endothelial cells in a selective 
way to induce leukocyte recognition as illustrated in the 
case of CCL21 [6]. This effect is significant enough for 
chemokines to be administered into the tumor in various 
therapeutic approaches [40].
As demonstrated previously, NK cell adhesion 
and cytotoxicity towards endothelial cells need IL-2 
stimulation of lymphocytes (NKL2, NKL3) [34, 36]. 
Adhesion is specific for lymphoid organ-derived ECs and 
integrin but it is not selectin dependent [36]. CCL21 is 
a potent chemoattractant for CCR7+ NK cells and takes 
part in lymphocyte homing by attracting circulating cells 
through the establishment of a concentration gradient 
[6, 36]. In addition to recognition, our research shows 
that adhesion occurring through CCL21 and its receptor 
requires dynamic clusterisation of CCR7 in NK cell 
membranes for tight interaction. But, the basal adhesion 
level of NK cells to HPLNEC.B3 cells indicates another 
mechanism in addition to the CCR7-dependent one. As 
far as the latter is concerned, the involvement of CCL21/
CCR7 axis was confirmed by the effect of external 
addition of CCL21 chemokine and efficient inhibition due 
to neutralizing anti CCR7- antibodies. The mechanism 
of CCL21 binding to endothelial cell surfaces is shown 
here as well as sugar structure specificity. Chondroitin 
sulfate was determined to be of the glycosaminoglycan 
type with which CCL21 interacts preferentially. The use 
of defined oligosaccharides allowed us to demonstrate 
the specificity for chondroitin sulfate type E. This 
molecular mechanism was observed in ECs vs NK cell 
Figure 6: MiRNA expression modulation in MSU 1.1 fibroblasts upon PDPN expression in normoxia and hypoxia. A. 
miR-210 increased expression by hypoxia in MSU1.1 and MSU 1.1 PDPN ; * p<0.05, N=3. B. miR-21 expression increase in MSU1.1 in 
hypoxia and in MSU1.1 PDPN by hypoxia. * p<0.05, N=3. C. hypoxia induced modulation of miR-29b expression in MSU1.1 and in MSU 
1.1 PDPN. * p<0.05, N=3.
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recognition and, noticeably, when compared to normoxia, 
hypoxia reduced NK cells adhesion, regardless of which 
treatment was used (CCL21, GAGs or CCR7-neutralizing 
antibodies). Recognition between ECs and NK cells was 
considerably lowered by hypoxia although it appeared 
to be still dependent on the CCL21/ChsE/CCR7 axis. 
This is in accordance with the observed impairment of 
NK cell action in tumor hypoxic sites. As other cancer 
cells, mammary carcinoma cells are able to metastasize 
into lymph nodes in a process involving the CCL21/
CCR7 axis [13]. This implies mobilization from the tumor 
primary site in which they interact with CAFs which are 
overexpressing podoplanin. Since CCL21 was found to 
interact with PDPN [10] the regulation of both molecules 
may control the entry of CCR7+NK cells and their 
cytotoxicity in the tumor. Furthermore, it may modulate 
the movement and escape of CCR7+tumor cells achieving 
metastasis. Moreover, CCR7 was shown to promote 
mammary cell tumorigenesis through amplification of 
stem-like cells [21] which points to the key role played by 
the CCL21/CCR7 axis in the various steps of mammary 
tumor evolution.
Overexpression of podoplanin results in a lower 
interaction of CAFs with carcinoma cells. As shown here, 
higher PDPN expression is due to hypoxia under which 
condition, the addition of CCL21 is required to help the 
CAF/cancer cell interaction. In comparison to normoxia 
we showed that CCL21 production is not increased 
upon hypoxia either in CAFs or in carcinoma cells. This 
confirms the anti-adhesive effect of podoplanin in the 
tumor microenvironment and its role in favoring CCR7+ 
carcinoma cell movement and mediating escape. CCR7+ 
carcinoma cells, as they are less retained in the primary 
tumor site, might thus be attracted to CCL21+ sites 
such as peripheral lymph nodes, where the chemokine 
is presented on endothelial cells as shown in this work. 
This participates to the understanding of the CCL21/CCR7 
impact on the activity and aggressiveness of cancer stem/
initiating cells in the hypoxic microenvironment [21, 41, 
42, 43]. Moreover, the importance of PDPN in the tumor 
microenvironment was confirmed by assessing the effect 
of its expression on micro RNAs (miR-21, miR-210, miR-
29b) that are involved in tumor development. MiR-21 is 
a known oncomiR which regulates tumor suppressors 
such as PTEN and p53 [30, 31] while miR-210 is the most 
active hypoxa- and angio- miR. MiR-29b regulates several 
proangiogenic molecules and podoplanin [40] which, 
moreover, appears to be positively regulated by hypoxia 
and co-expressed with miR-21 and miR-210. Since miR-
29b is a down regulator of podoplanin, its overexpression 
in hypoxia in cells, as well as conditions which induce 
podoplanin expression, suggests a sequential, time-
dependent and hypoxia-dependent regulatory effect. This 
work points to the important part played by hypoxia in the 
regulation of podoplanin in tumors and its interaction with 
CCL21. It shows the key role of hypoxia in the restriction 
of immune cell recruitment favoring immunosuppression. 
It also demonstrates the part played by CCR7+ tumor cell 
adhesion to tumor fibroblasts in helping the dissemination 
of CCR7+, tumor cells which are potentially aggressive 
cancer stem cells [21, 43].
MATERIALS AND METHODS
Cell cultures
Immortalized HPLNEC.B3 endothelial cell lines 
used in this study display the general characteristics of 
the in vivo endothelium phenotype [e.g. the presence of 
angiotensin converting enzyme (ACE), the von Willebrand 
factor and vascular endothelial (VE)-cadherin]. Human 
microvascular ECs were isolated and immortalized 
according to the method previously described and 
patented [35]. The HPLNEC.B3 cells were cultured in 
OptiMEM with Glutamax-I (Invitrogen, Cergy Pontoise, 
France) supplemented with 2% MycoPlex FBS (PAA, Les 
Mureaux, France), 40 μg/ml gentamycin (Invitrogen) and 
0.05 μg/ml fungizone (Invitrogen).
The NKL cell line was established from the 
peripheral blood of a patient with large granular 
lymphocyte leukemia as previously described [33]. 
NKL cells were maintained in culture in OptiMEM 1 
with Glutamax-I (Invitrogen), supplemented with 3% 
human AB serum (Institut Jacques Boy), 1% penicillin/
streptomycin (Invitrogen), and 0.05 μg/ml fungizone. 
Additionally, for NKL2 and NKL3 clones [33] culture, 200 
U/ml of human interleukin-2 (IL-2) (Roche Diagnostics, 
Germany) were added.
All the cells were maintained at 37°C in a 5% 
CO2/95% air atmosphere.
Hypoxia treatment
Cells were maintained under hypoxic conditions for 
24 hours by flowing a 5% CO2, 95% N2 gas mixture in an 
automated PROOX chamber (C-174, BioSpherix, USA). 
An 1% oxygen level was controlled by a PROOX sensor 
(model 110, BioSpherix).
mAbs and reagents
Mouse IgG2A anti human CCR7 fluorescein-
coupled antibodies, mouse IgG2a fluorescein-coupled 
isotypic control, mouse IgG2A anti human CCR7 
neutralizing antibodies, recombinant human CCL21 and 
human CCL21 ELISA kits were purchased from R&D 
Systems (UK). Chondroitin sulfate E was obtained from 
Seikagaku Corp. (Japan). The PKH26GL Red Fluorescent 
Cell Linker kit and fibronectin were purchased from 
Sigma-Aldrich (France).
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Expression of CCR7 on NK cells
During all the labelling procedures, cells were 
maintained at 4°C. 5.105 cells were washed twice with 
complete phosphate-buffered saline (cPBS) (1 mM CaCl2 
and 0.5 mM MgCl2), 0.5% bovine serum albumin (BSA) 
[weight/volume (w/v)] (Sigma-Aldrich). Then, cells were 
incubated in the presence of 2.5 μg/ml mouse IgG2A anti 
human CCR7 fluorescein-coupled antibodies for 1 hour 
at 4°C. Cells were washed twice with cPBS and analyzed 
by flow cytometry on a FACS LSR II apparatus (Becton 
Dickinson, Sunnyvale, CA) using CELLQUEST software 
(Becton Dickinson).
Capping of CCR7
NK cells were labelled at 4°C as previously 
described. Then, receptor rearrangement was visualized by 
fluorescent microscopy raising the cell temperature from 
4°C to room temperature. Cell fluorescence was observed 
with the use of an Axiovert 200 epifluorescence inverted 
microscope (Zeiss, Le Pecq, France). Pictures were taken 
every 5 minutes at room temperature.
Flow adhesion experiments
Flow adhesion experiments used either a flow 
chamber (Immunetics, Boston, MA) as previously 
described [44] or the BioFlux system (Labtech, France). 
Forty-eight hours before the experiment, HPLNEC.B3 
cells were seeded either on polystyrene tissue-culture 
slides (Nagle Nunc International) or on a 48-well BioFlux 
plate, according to the manufacturer’s instructions. Briefly, 
channels on the Bioflux plate were coated with 50 μg/ml of 
fibronectin (Sigma, France). Then, cells were seeded into 
the channels and 5 hours later, the medium was removed 
from the outlet well to allow a passive flow of medium. 
Forty-eight hours after seeding, HPLNEC.B3 cells were 
either treated or not treated with CCL21 chemokine and/
or GAGs. Cells were incubated in basal OptiMEM for 1 
hour at 37°C with 17 nM or 50 nM of human recombinant 
CCL21 on a culture slide and a 48-well Bioflux plate, 
respectively or with 0.6 μg/ml of chondroitin sulfate E 
(ChSE, Seikagaku, Japan). When CCL21 was combined 
with ChSE for treatments, chemokine was pre-incubated 
15 minutes at room temperature with ChSE and then 
added to the cells for 1 hour at 37°C.
For image acquisition, the flow chamber or 
the Bioflux plate was mounted on an Axiovert 200 
epifluorescence inverted microscope (Zeiss) for direct 
real-time visualization of the dynamic cell adhesion 
process using a X10 objective. The microscope was 
coupled to an Axiocam high-resolution numeric camera 
(Carl Zeiss) attached directly to a computer equipped with 
the acquisition software Axiovision (Zeiss).
CCL21 secretion by HPLNEC.B3 cells under 
normoxia and hypoxia
HPLNEC.B3 cells were cultured for 24 hours 
under hypoxia or normoxia. Then cells were lysed with 
lysis buffer (1% Triton X-100; Sigma, Protease Inhibitor 
Cocktail; Roche). The protein content in each sample was 
quantified with a BCA-based method (Thermo Fisher 
Scientific Inc., France).
GAG biotinylation procedure
GAGs (chondroitin sulfate A, B, C, D, E, heparan 
sulfate, keratan sulfate and hyaluronic acid, from 
Seikagaku Corp. (Japan), re-suspended in PBS at 10 mg/
ml, were allowed to react under agitation for 24 h at room 
temperature with 10 mM biotin/LC-hydrazine (Perbio 
Science, Brebières, France). To remove unreacted biotin-
LC-hydrazide, each reaction mixture was applied to a 
Trisacryl GF05 M (BioSepra, Villeneuve La Garenne, 
France) column. The fractions containing biotinylated 
GAGs were detected using a calorimetric method using 
resorcinol and sulfuric acid [45].
Kinetic analysis using BIAcore
The experiment was performed on a BIAcoreTM 
2000 system (BIAcore AB, Uppsala, Sweden). All 
experiments were performed at 25°C. Sensor chips SA 
(BIAcore AB) were used. Chips were first conditioned 
with three consecutive 1 minute injections of 1 M NaCl 
in 50 mM NaOH.
Biotinylated GAGs, diluted in HBS (10 mM Hepes, 
150 mM NaCl, 3.4 mM EDTA, 0.005% surfactant P20, 
pH 7.4, BIAcore) containing 0.3 M NaCl, were injected on 
one flow cell of the chip SA. The first flow cell was used 
as a negative control. Approximately 100 resonance units 
(RU) of material were immobilized for each GAG.
The running buffer used for the washing and 
dissociation phases was PBS-BSA 0.2%.
For the binding assays, different concentrations of 
chemokines were injected at 30 μl/min for CCL5 and 50 
μl/min for CCL21, to eliminate mass transport effects. 
The sensor chip surface was regenerated with a 1-minute 
injection of 1 M NaCl. No significant change in the 
baseline was observed after surface regeneration. Affinity 
kinetic parameters were determined with BIAevaluation 
3.0 software (BIAcore) using a single-site binding model.
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